title: Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response.
abstract: OBJECTIVE
  To determine if immunological response is associated with disease progression in patients with virological suppression after initiating HAART.
  
  
  METHODS
  A cohort study of 1084 treatment-naive participants in the British Columbia HIV/AIDS Drug Treatment Program who had achieved viral loads < 500 copies/ml at 3-9 months after initiating triple-drug therapy.
  
  
  METHODS
  Cox proportional hazards was used to model the association with disease progression of baseline variables, change in CD4 cell counts and CD4 cell count strata at 6 months. Logistic regression analysis was used to examine associations with two definitions of poor immunological response.
  
  
  RESULTS
  Patients were followed for a median of 51.4 months. In univariate analyses, increases in CD4 cell counts of < 25 cells/microl and absolute CD4 cell counts of < 200 cells/microl were associated with an increased risk of death or new AIDS events. Two mulitivariate models, one including baseline CD4 cell count and change in CD4 cell count from baseline and the other including only absolute CD4 cell counts at 6 months, were found to predict disease progression in this setting. Increases in CD4 cell count of < 25 cells/microl were associated with increasing age and inversely associated with low baseline CD4 cell counts, high baseline viral loads and good adherence to therapy. CD4 cell counts of < 200 cells/microl at 6 months were associated with low baseline CD4 cell counts and having AIDS at baseline.
  
  
  CONCLUSIONS
  Patients with virological suppression are still at risk for HIV disease progression if adequate immunological responses are not achieved.
authors.affiliation: BC Centre for Excellence in HIV/AIDS, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. dmoore@cfenet.ubc.ca
authors.forename: David M
authors.initials: DM
authors.lastname: Moore
authors.forename: Robert S
authors.initials: RS
authors.lastname: Hogg
authors.forename: Keith
authors.initials: K
authors.lastname: Chan
authors.forename: Mark
authors.initials: M
authors.lastname: Tyndall
authors.forename: Benita
authors.initials: B
authors.lastname: Yip
authors.forename: Julio S G
authors.initials: JS
authors.lastname: Montaner
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D008297:Male; D015999:Multivariate Analysis; D012307:Risk Factors; D019562:Viral Load